These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 23570985)

  • 1. Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs.
    Nkansah P; Antipas A; Lu Y; Varma M; Rotter C; Rago B; El-Kattan A; Taylor G; Rubio M; Litchfield J
    J Control Release; 2013 Jul; 169(1-2):150-61. PubMed ID: 23570985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
    Rasool BK; Fahmy SA; Galeel OW
    Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and Evaluation of Novel Solid Self-Nanodispersion Delivery System for Andrographolide.
    Xu J; Ma Y; Xie Y; Chen Y; Liu Y; Yue P; Yang M
    AAPS PharmSciTech; 2017 Jul; 18(5):1572-1584. PubMed ID: 27620195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
    Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
    Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent.
    Tran TH; Poudel BK; Marasini N; Chi SC; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2013 Feb; 443(1-2):50-7. PubMed ID: 23318367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound.
    Tong HH; Du Z; Wang GN; Chan HM; Chang Q; Lai LC; Chow AH; Zheng Y
    Int J Pharm; 2011 Feb; 404(1-2):148-58. PubMed ID: 21094233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions.
    De Zordi N; Moneghini M; Kikic I; Grassi M; Del Rio Castillo AE; Solinas D; Bolger MB
    Eur J Pharm Biopharm; 2012 May; 81(1):131-41. PubMed ID: 22266263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals.
    Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z
    Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
    Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
    Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
    Patel GV; Patel VB; Pathak A; Rajput SJ
    Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats.
    Nielsen LH; Rades T; Müllertz A
    Int J Pharm; 2015 Jul; 490(1-2):334-40. PubMed ID: 26026252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.
    Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New oral solid dosage form for furosemide oral administration.
    Perioli L; D'Alba G; Pagano C
    Eur J Pharm Biopharm; 2012 Apr; 80(3):621-9. PubMed ID: 22230797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations.
    Liu Y; Salituro GM; Lee KJ; Bak A; Leung DH
    AAPS PharmSciTech; 2015 Oct; 16(5):1091-100. PubMed ID: 25690735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding.
    Wu JZ; Ho PC
    Eur J Pharm Sci; 2006 Sep; 29(1):35-44. PubMed ID: 16824739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
    Merisko-Liversidge E; Liversidge GG
    Adv Drug Deliv Rev; 2011 May; 63(6):427-40. PubMed ID: 21223990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Strategy for the Systemic Delivery of Furosemide Based on a New Drug Transport Mechanism.
    Kimura S; Kiriyama A; Nishimura E; Sakata S; Inoue D; Furubayashi T; Yutani R; Tanaka A; Kusamori K; Katsumi H; Iga K; Yamamoto A; Sakane T
    Biol Pharm Bull; 2018; 41(12):1769-1777. PubMed ID: 30504679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two- and three-layer tablet drug delivery systems for oral sustained release of soluble and poorly soluble drugs.
    Efentakis M; Naseef H; Vlachou M
    Drug Dev Ind Pharm; 2010 Aug; 36(8):903-16. PubMed ID: 20196641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.